RZNOMICS
This is a biotechnology company founded by professor Lee Sung-wook's lab They are working on the development of gene therapy products for liver cancer through the development of gene therapy products. It was selected by the TIPS program and was recognized for excellence in technology.
RZNOMICS
Industry:
Biopharma Biotechnology
Founded:
2017-08-01
Address:
Gwangju, Kwangju-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.rznomics.com
Total Employee:
11+
Status:
Active
Contact:
+82 62-974-2905
Total Funding:
59.7 B KRW
Technology used in webpage:
IPhone / Mobile Compatible SPF Mobile Non Scaleable Content Nginx Microsoft Exchange Online Office 365 Mail UNPKG Korea Telecom
Similar Organizations
Faze Medicines
Faze Medicines is a biotechnology company.
GE Holdings Japan
GE Holdings is a biotechnology based company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
Repertoire Genesis
Repertoire Genesis is a biotechnology company.
Current Employees Featured
Seongwook Lee CEO & Founder @ Rznomics
CEO & Founder
2017-09-01
Founder
Investors List
Aon plc
Aon plc investment in Series C - Rznomics
SBI Investment Korea
SBI Investment Korea investment in Series C - Rznomics
Quad Ventures
Quad Ventures investment in Series C - Rznomics
Shinhan Venture Investment
Shinhan Venture Investment investment in Series C - Rznomics
IBK Capital
IBK Capital investment in Series C - Rznomics
Partners Investment
Partners Investment investment in Series C - Rznomics
UTC Investment Co.
UTC Investment Co. investment in Series C - Rznomics
Korea Development Bank
Korea Development Bank investment in Series C - Rznomics
Synergy IB Investment
Synergy IB Investment investment in Series B - Rznomics
Partners Investment
Partners Investment investment in Series B - Rznomics
Official Site Inspections
http://www.rznomics.com
- Host name: 183.111.183.33
- IP address: 183.111.183.33
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Rznomics"
Rznomics
About Rznomics. 혁신적 RNA 기반 바이오 신약 개발을 통한 인체질환정복 구현을 위해 간암/범용 각종 암/퇴행성 질환/유전 질환에 대한 유전자 치료제 개발을 목표로 하고 있습니다.See details»
Rznomics - Crunchbase Company Profile & Funding
Rznomics is located in Gwangju, Kwangju-jikhalsi, South Korea. Who invested in Rznomics? Rznomics has 14 investors including Aon and SBI Investment Korea. How much funding has …See details»
Rznomics Inc. - LinkedIn
Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme.See details»
Rznomics Company Profile 2024: Valuation, Funding
Developer of ribonucleic acid-based gene therapies designed to create new bio drugs for cancer and intractable diseases with highly medical unmet needs.See details»
RZNOMICS Inc. received FDA approval to initiate clinical …
SEONGNAM, South Korea, Oct. 25, 2022 /PRNewswire/ -- Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, …See details»
Charles River and Rznomics Ink RNA-Based Anticancer Gene …
Jan 20, 2023 · Charles River Laboratories International and Rznomics Inc. have announced a viral vector contract development and manufacturing partnership around mRNA-based gene …See details»
Rznomics - Funding, Financials, Valuation & Investors - Crunchbase
Rznomics is a biotechnology company.See details»
Rznomics Company Profile - Office Locations, Competitors ... - Craft
Rznomics is a biotech research company. It is engaged in the development of gene therapy products for liver cancer. Rznomics $10.28 m in total funding,. See insights on Rznomics …See details»
Rznomics Inc. Secures Orphan Drug Designation from FDA for RZ …
Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, has received an Orphan Drug Designation from the U.S. …See details»
Rznomics' RNA-Based Therapy Receives FDA Orphan …
Feb 2, 2024 · The South Korean biopharmaceutical company Rznomics Inc. has announced that its novel RNA-based therapy, RZ-001, designed for the treatment of Hepatocellular Carcinoma (HCC), has been granted Orphan Drug …See details»
Charles River and Rznomics Announce RNA-based ... - Business Wire
Jan 18, 2023 · Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients.See details»
Rznomics Inc. Secures Fast Track Designation from the U.S. FDA …
Nov 10, 2023 · Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced today that it has received Fast …See details»
Rznomics Inc. Secures Orphan Drug Designation from FDA for RZ …
SEONGNAM, South Korea, Feb. 2, 2024 /PRNewswire/ -- Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, …See details»
SK pharmteco and Rznomics Explore Collaboration for RNA-based …
Rznomics is a South Korea-based innovative RNA biopharmaceutical company with a vision to treat and conquer various human intractable diseases. Rznomics has developed and focused …See details»
RZNOMICS Inc. received FDA approval to initiate clinical …
Oct 25, 2022 · SEONGNAM, South Korea — Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, …See details»
Charles River and Rznomics Announce RNA-based Anticancer …
Jan 18, 2023 · Charles River Laboratories International, Inc. and Rznomics Inc., a South Korea- based biopharmaceutical company specialized in the development of RNA-based gene …See details»
Charles River and Rznomics Partner on RNA-based Anticancer …
Jan 23, 2023 · Charles River Laboratories and Rznomics, a South Korea-based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, …See details»
Rznomics Inc. Secures Fast Track Designation from the U.S. FDA …
Nov 10, 2023 · As a biopharmaceutical company founded in the laboratory of Professor Seong-Wook Lee, Dankook University Department of Bioconvergence Engineering, Rznomics is …See details»
RZNOMICS Inc. received FDA approval to initiate ... - Pipelinereview
Oct 26, 2022 · Ribozyme-based RNA editing technology developed by Rznomics has unique features, differentiating it from other nucleic acid-based editing approaches, as follows: (1) A …See details»
Rznomics Presents Its Own Circular RNA Platform Technology - PR …
Aug 3, 2023 · Rznomics applied its unique Tetrahymena trans-splicing ribozyme platform technology to effectively convert linear RNA into circular RNA by designing end-to-end self …See details»